Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A promising combo falls just short of the finish line. Interim data from the phase 3 DUO-E trial showed that adding durvalumab and olaparib to standard chemotherapy extended median overall survival to 51.1 months vs. 39.6 months with chemo alone in advanced endometrial cancer — but the result narrowly missed statistical significance. A final analysis is still on the horizon.
A promising combo falls just short of the finish line
The phase 3 DUO-E trial tested whether adding the immunotherapy durvalumab (Imfinzi) and the PARP inhibitor olaparib (Lynparza) to standard carboplatin/paclitaxel chemotherapy could improve survival in patients with advanced or recurrent endometrial cancer. At the second interim analysis — presented at the 2026 ESMO Congress — the durvalumab plus olaparib arm showed a median overall survival (OS) of 51.1 months vs. 39.6 months in the chemo-only control arm. That's a meaningful 11.5-month difference, but it narrowly missed the prespecified statistical threshold.
The durvalumab-alone arm also trended better than control (40.7 vs. 39.6 months), but again fell short of significance. Importantly, OS will be formally retested at the final analysis, keeping the door open for this regimen.
By the Numbers
Why it matters: Endometrial cancer is the most common gynecologic malignancy, and options for advanced disease remain limited. While the interim OS data didn't cross the significance threshold, the consistent trend — especially in dMMR patients — suggests this combination could still prove meaningful at final analysis, potentially reshaping first-line treatment strategies.
